The World Health Organization has admitted that talks aimed at encouraging governments to share avian influenza virus samples have stalled. The problem arises out of Indonesia (where almost half of all human deaths from the H5N1 disease have occurred since 2003) and which has about 235 million inhabitants. The government there insists on guarantees that any drugs developed with the assistance of Indonesian virus samples must be made available in priority at an affordable level to the Indonesian population. The authorities also want intellectual property rights to be shared with the countries where the samples originate from.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze